High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas
- PMID: 1720630
- DOI: 10.1089/aid.1991.7.831
High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas
Abstract
Neutralizing antibodies (NA) against HIV-1MN and HIV-1IIIB, and antibodies binding to synthetic peptides (BA) derived from the gp120 envelope V3 region principal neutralizing determinants (PND) of the HIV-1MN, HIV-1IIIB, and HIV-1Z3 virus strains were assayed in HIV-1 antibody-positive sera from the United States, Haiti, Brazil, Zaire, and Zimbabwe. The ability of soluble PND peptide to block neutralization of the corresponding virus by representative sera was also tested. In each country, NA and BA titers were highest against the HIV-1MN strain, and compared with other countries, NA and BA titers against HIV-1MN were higher in sera from the United States and Haiti. When NA titers were compared with BA titers against either HIV-1MN or HIV-1IIIB, no correlation was found for the HIV-1IIIB strain, but there was a significant correlation for HIV-1MN. Addition of the HIV-1MN strain peptide to a neutralization assay for HIV-1MN resulted in a four- to tenfold reduction in NA titers in sera from the United States, Zaire, and Brazil. The results suggest that HIV-1MN and closely related variants are prevalent in many parts of the world, and that antibodies directed against the PND account for most of the neutralizing activity in sera of infected individuals.
PIP: Virologists assessed the extent of neutralizing antibody cross-reactivity to multiple virus strains in sera from 112 HIV-1 infected individuals from the US, Brazil, Haiti, Zaire, and Zimbabwe. They also looked at the association between virus neutralization and the level of antibody binding to synthetic peptides representing the HIV-1 gp120 V3 region principal neutralizing determinant (PND) sequences. The 3 strains observed included HIV-1 MN, HIV-1 Z3, and HIV-1 IIIB. Neutralizing antibodies (NA) and antibodies binding to synthetic peptides (BA) titers ranked highest against the PND sequence HIV-1 MN in all countries (p.01). These titers were higher in sera from the US and Haiti than sera from Brazil and Africa (p.05). A significant correlation existed between the NA and BA titers for HIV-1 MN (p.01), but not for HIV-1 IIIB. When the virologists added HIV-1 MN strain peptide to a neutralization assay for HIV-1 MN, NA titers in sera from the US, Zaire, and Brazil fell 4-10 fold. These findings intimated that HIV-1 MN and closely related variants are commonplace in several locations around the world, and that antibodies directed against HIV--1 gp120 V3 region PND sequences make up most of the neutralizing activity in sera of infected individuals. In conclusion, virologists need to conduct more studies that examine the true extent of strain variation worldwide. These studies could lay the groundwork for the development of an effective HIV-1 vaccine.
Similar articles
-
Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.J Virol. 1992 Sep;66(9):5210-5. doi: 10.1128/JVI.66.9.5210-5215.1992. J Virol. 1992. PMID: 1380094 Free PMC article.
-
Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.AIDS Res Hum Retroviruses. 1994 Nov;10(11):1551-6. doi: 10.1089/aid.1994.10.1551. AIDS Res Hum Retroviruses. 1994. PMID: 7534097
-
The majority of neutralizing Abs in HIV-1-infected patients recognize linear V3 loop sequences. Studies using HIV-1MN multiple antigenic peptides.J Immunol. 1994 Aug 15;153(4):1895-904. J Immunol. 1994. PMID: 7519220
-
[Peptides from the principal neutralizing and CD4-binding domain: similar immunoreactive properties and structure pattern].Vestn Ross Akad Med Nauk. 1992;(9-10):47-52. Vestn Ross Akad Med Nauk. 1992. PMID: 1283721 Review. Russian.
-
Antigenic and immunogenic sites of HIV-2 glycoproteins.Chem Immunol. 1993;56:61-77. doi: 10.1159/000319156. Chem Immunol. 1993. PMID: 8452654 Review.
Cited by
-
Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.J Virol. 1992 Sep;66(9):5210-5. doi: 10.1128/JVI.66.9.5210-5215.1992. J Virol. 1992. PMID: 1380094 Free PMC article.
-
Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.J Virol. 2003 Oct;77(20):11125-38. doi: 10.1128/jvi.77.20.11125-11138.2003. J Virol. 2003. PMID: 14512560 Free PMC article.
-
Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities.Arch Virol. 1995;140(8):1393-404. doi: 10.1007/BF01322666. Arch Virol. 1995. PMID: 7544970
-
Cellular and humoral antigenic epitopes in HIV and SIV.Immunology. 1992 Aug;76(4):515-34. Immunology. 1992. PMID: 1383131 Free PMC article. Review. No abstract available.
-
Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens.Structure. 2009 Nov 11;17(11):1538-46. doi: 10.1016/j.str.2009.09.012. Structure. 2009. PMID: 19913488 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources